Ubs Group Ag Oncolytics Biotech Inc Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Oncolytics Biotech Inc stock. As of the latest transaction made, Ubs Group Ag holds 22,896 shares of ONCY stock, worth $24,040. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,896

Previous 20,796 10.1%

Holding current value

$24,040

Previous $16,000 100.0%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$0.75 - $1.43 $1,575 - $3,003	2,100 Added 10.1%	22,896 $32,000
Q2 2025 Aug 14, 2025	SELL	$0.33 - $0.77 $33 - $78	-102 Reduced 0.49%	20,796 $16,000
Q4 2024 Feb 14, 2025	SELL	$0.74 - $1.4 $1,508 - $2,853	-2,038 Reduced 8.89%	20,898 $19,000
Q3 2024 Nov 14, 2024	BUY	$0.87 - $1.08 $15,079 - $18,719	17,333 Added 309.35%	22,936 $19,000
Q2 2024 Aug 13, 2024	BUY	$0.99 - $1.24 $4,394 - $5,504	4,439 Added 381.36%	5,603 $5,000

Q1 2024 May 13, 2024	SELL	$0.89 - $1.36 $3,146 - $4,807	-3,535 Reduced 75.23%	1,164 $1,000
Q4 2023 Feb 09, 2024	SELL	$1.22 - $2.09 $3,618 - $6,198	-2,966 Reduced 38.7%	4,699 $6,000
Q3 2023 Nov 09, 2023	SELL	$1.98 - $3.24 $11,462 - $18,756	-5,789 Reduced 43.03%	7,665 $16,000
Q2 2023 Aug 11, 2023	BUY	$1.11 - $2.74 $4,777 - $11,792	4,304 Added 47.04%	13,454 $34,000
Q1 2023 May 12, 2023	BUY	$1.2 - $1.91 $1,782 - $2,836	1,485 Added 19.37%	9,150 $10,000
Q3 2022 Nov 10, 2022	SELL	$0.98 - $1.51 $2,506 - $3,862	-2,558 Reduced 25.02%	7,665 $9,000
Q2 2022 Aug 10, 2022	BUY	$0.85 - $1.59 $8,549 - $15,992	10,058 Added 6095.76%	10,223 $11,000
Q1 2022 May 16, 2022	SELL	$1.31 - $2.02 $4,113 - $6,342	-3,140 Reduced 95.01%	165 $0
Q4 2021 Feb 14, 2022	SELL	$1.39 - $2.3 $32,644 - $54,015	-23,485 Reduced 87.66%	3,305 $4,000
Q3 2021 Nov 15, 2021	BUY	$1.93 - $2.77 $11,774 - $16,899	6,101 Added 29.49%	26,790 $56,000
Q2 2021 Aug 13, 2021	BUY	$2.6 - $4.64 $48,300 - $86,197	18,577 Added 879.59%	20,689 $57,000
Q1 2021 May 12, 2021	BUY	$2.32 - $4.11 $4,519 - $8,006	1,948 Added 1187.8%	2,112 $8,000
Q2 2020 Jul 31, 2020	SELL	$1.33 - $2.76 $771 - $1,600	-580 Reduced 77.96%	164 $0
Q1 2020 May 01, 2020	SELL	$0.98 - $4.28 $2,210 - $9,655	-2,256 Reduced 75.2%	744 $1,000
Q4 2019 Feb 14, 2020	BUY	$0.42 - $4.76 $947 - $10,738	2,256 Added 303.23%	3,000 $14,000
Q2 2019 Aug 14, 2019	BUY	$1.63 - $1.95 $84 - $101	52 Added 7.51%	744 $1,000
Q1 2019 May 14, 2019	SELL	$1.77 - $2.31 $212 - $277	-120 Reduced 14.78%	692 $1,000
Q4 2018 Feb 14, 2019	SELL	$1.72 - $4.12 $9,014 - $21,592	-5,241 Reduced 86.59%	812 $1,000
Q3 2018 Nov 14, 2018	BUY	$3.83 - $5.92 $6,748 - $10,431	1,762 Added 41.06%	6,053 $24,000
Q2 2018 Aug 14, 2018	BUY	$4.56 - $7.83 $19,566 - $33,598	4,291 New	4,291 $24,000

Others Institutions Holding ONCY

# of Institutions

Shares Held

2.82M

Call Options Held

Put Options Held

View Full List

About ONCOLYTICS BIOTECH INC

Ticker ONCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,867,400
Market Cap $60.8M
Description
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a...

More about ONCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account